Amgen announced positive Phase 3 OASIZ-301 trial results for dazodalibep, a CD40L antagonist, showing significant and meaningful reductions in systemic disease activity and patient-reported dryness in adults with moderate-to-severe Sjögren's disease. The drug demonstrated improvements as early as four weeks and was well tolerated with similar adverse event rates to placebo. These findings address a critical unmet need, as there are currently no FDA-approved treatments for Sjögren's disease. Amgen will also present additional data on other rare autoimmune disease treatments at ACR Convergence 2026, highlighting its commitment to rare diseases.
Amgen's stock price rose by 1.81% to USD 452.70 as of Oct 28, 2026 03:11 WIB on Pluang. The company's market capitalization stands at $240.38 billion, reflecting its significant presence in the health sector. Despite positive trial results, current Pluang order activity shows 100% sell interest in AMGN shares at this time.
Amgen Inc. will announce its Q3 earnings on November 3, following a strong Q2 where non-GAAP EPS rose 25.8% to $6.29, driven by biosimilars and key drugs like Blincyto and Repatha. Recently, Amgen reported encouraging results from a lung cancer drug ...
Amgen has appointed David W. Gibbs, former CEO of Yum! Brands, to its Board of Directors. Gibbs brings extensive leadership experience from the consumer brand sector and will serve on Amgen's Audit and Compensation Committees. His background in digit...
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi immunotherapy reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, extending median survival to 21.1 months from 12.7 months with Imf...
Amgen announced Phase 3 DeLLphi-305 trial results where IMDELLTRA combined with AstraZeneca's IMFINZI reduced death risk by 58% and extended median overall survival to 21.1 months in extensive-stage small cell lung cancer patients. Nearly 80% of pati...
